Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(4-aminobutyl)-4-sulfamoylbenzamide is a synthetic small molecule belonging to the benzamide sulfonamides. It features a sulfonamide group attached to a benzene ring and an aminobutyl side chain. This compound is part of a class of molecules known as benzamide-4-sulfonamides, which have been studied primarily as potent inhibitors of the metalloenzyme carbonic anhydrase (CA), particularly human isoforms hCA II, VII, and IX. These enzymes are involved in physiological processes such as intraocular pressure regulation and acid-base balance. The compound has demonstrated low nanomolar or subnanomolar inhibitory activity against these CA isoforms *in vitro*, suggesting potential utility for conditions like glaucoma or other diseases where carbonic anhydrase inhibition is beneficial[6]. Its development status remains experimental.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(4-aminobutyl)-4-sulfamoylbenzamide.